BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
rs2230926
,
TGFB1
,
G-protein-coupled receptor binding
,
Ischemia
,
Hippocampus
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
rimonabant
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
PBMCs of obese humans before and during treatment with rimonabant
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
Explore Curated Studies Results
Literature
Most Relevant Literature
Efficacy of rimonabant in obese patients with binge eating disorder.
Novel antiobesity agents: synthesis and pharmacological evaluation of analogues of Rimonabant and of…
Low dose naloxone attenuates the pruritic but not anorectic response to rimonabant in male rats.
Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emoti…
Effect of chronic exposure to rimonabant and phytocannabinoids on anxiety-like behavior and sacchari…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Interaction Between Rimonabant and Cyclosporine and Tacrolimus
Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant
The Effects of Rimonabant, on Weight and Metabolic Risk Factors
The Effect of Rimonabant on Energy Expenditure, Fat Metabolism and Body Composition
Rimonabant to Reduce Alcohol Consumption
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ